Sort   by:  
 Page size 
UnknownPredominantly Persistent Intraretinal Fluid in the Comparison of Age-related Macular Degeneration Treatments Trials.
Not available
S-EPMC10282893 | biostudies-literature
UnknownRanibizumab and bevacizumab for neovascular age-related macular degeneration.
Not available
S-EPMC3157322 | biostudies-literature
UnknownOutcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Not available
S-EPMC4766028 | biostudies-literature
UnknownOutcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
Not available
S-EPMC4306628 | biostudies-literature
UnknownSporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Not available
S-EPMC4301065 | biostudies-literature
UnknownThiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials.
Not available
S-EPMC10245276 | biostudies-literature
UnknownProgression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.
Not available
S-EPMC6246813 | biostudies-literature
UnknownNatural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17.
Not available
S-EPMC6348044 | biostudies-literature
UnknownAflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Not available
S-EPMC4422053 | biostudies-literature
UnknownBaseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
Not available
S-EPMC3536921 | biostudies-literature
Sort   by:  
 Page size